

1 **An autosomal dominant cardiac arrhythmia syndrome, ST Depression**
2 **Syndrome, is caused by the *de novo* creation of a cardiomyocyte enhancer.**

3

4 Carin P. de Villiers^{1†}, Damien J. Downes^{2†}, Anuj Goel^{1,3}, Alistair T. Pagnamenta³, Elizabeth
5 Ormondroyd¹, Alexander J. Sparrow¹, Svanhild Nornes^{4,5}, Edoardo Giacomuzzi^{3,6}, Phalguni
6 Rath³, Ben Davies³, Ron Schwessinger^{2,7}, Matthew E. Gosden², Robert A. Beagrie^{3,8},
7 Duncan Parkes³, Rob Hastings¹, Stefano Lise^{3,9}, Silvia Salatino³, Hannah
8 Roberts³, Maria Lopopolo³, Carika Weldon³, Amy Trebes³, The WGS500 consortium¹⁰,
9 David Buck³, Jenny C. Taylor³, Charles Redwood¹, Edward Rowland¹¹, Dushen
10 Tharmaratnam¹², Graham Stuart¹³, Pier D. Lambiase¹¹, Sarah De Val^{4,5}, Jim R. Hughes^{2,7*},
11 Hugh Watkins^{1,3*}

12

13 † These authors contributed equally: Carin P. de Villiers & Damien J. Downes.

14 * Corresponding authors: hugh.watkins@rdm.ox.ac.uk, jim.hughes@imm.ox.ac.uk

15

16 **Affiliations:**

17 1 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
18 Oxford, Oxford, UK

19 2 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine,
20 Radcliffe Department of Medicine, University of Oxford, Oxford, UK

21 3 Centre for Human Genetics, University of Oxford, Oxford, UK

22 4 Ludwig Institute for Cancer Research Ltd, Nuffield Department of Medicine,
23 University of Oxford, Oxford, UK

24 5 Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

25 6 Human Technopole, Milan, Italy

26 7 MRC WIMM Centre for Computational Biology, MRC Weatherall Institute of
27 Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford,
28 UK

29 8 Laboratory of Gene Regulation, MRC Weatherall Institute of Molecular Medicine,
30 Radcliffe Department of Medicine, University of Oxford, Oxford, UK

31 9 University College London Cancer Institute, London, UK

32 10 Contributors listed at the end of the manuscript

33 11 St Bartholomew's Hospital, Barts Health NHS Trust, London, UK and UCL Institute of
34 Cardiovascular Science, University College London, London, UK

35 12 Royal Devon University Healthcare NHS Foundation Trust

36 13 Bristol Heart Institute, Bristol, United Kingdom

37

38

39 **Keywords:** Enhancer, KCNB1, ECG, ST-segment, Arrhythmia, Mendelian disease,

40 gene regulation, machine learning

41 **Abstract**

42 A substantial proportion of mutations underlying rare Mendelian diseases remain unknown,
43 potentially because they lie in the non-coding genome. Here, we report the mapping of the
44 causal mutation of an autosomal dominant cardiac arrhythmia syndrome, ST Depression
45 Syndrome, which is associated with widespread ST-depression on the electrocardiogram
46 together with risk of sudden death and heart failure, to the non-coding region of the *KCNB1*
47 locus. Using genetic linkage analysis, we narrowed the associated region to 1cM of the
48 genome and then with a genome editing approach, we show that the mutation, a small
49 complex insertion-deletion, generates a *de novo* gain-of-function enhancer that drives higher
50 expression of *KCNB1* in cardiomyocytes. This is the first report of a gain of *de novo*
51 enhancer function causing Mendelian disease. Critically, the tissue-specific gain-of-function
52 regulatory change could be predicted using a deep neural network. Application of a similar
53 framework will enable identification of causal non-coding mutations and affected genes in
54 other rare diseases.

55 Introduction

56

57 In the last decade, advances in sequencing technologies have produced a wealth of data for
58 understanding the causes of Mendelian disease, however, variant interpretation and
59 identification of disease-causing mutations is still incomplete. Current approaches detect a
60 pathogenic variant in only a third of patients with suspected genetic disease¹⁻⁴, with the vast
61 majority of them located in the coding part of the genome. Candidate gene panels, whole
62 exome sequencing (WES), and certain bioinformatic variant filtering approaches using whole
63 genome sequencing (WGS) data⁵, still frequently miss or disregard non-coding variants. This
64 is partly due to a huge gap in knowledge concerning these parts of the genome. However,
65 just as the majority of common disease variants are thought to affect regulatory, rather than
66 coding sequence⁶, there are likely to be a number of primary disease-causing mutations
67 affecting non-coding regulatory elements that are currently going undetected⁷. Additionally,
68 within efforts to define disease-causing non-coding variants, most emphasis is on detecting
69 variants that disrupt annotated regulatory elements, with few efforts directed at detecting
70 newly created elements and gain-of-function changes. Bridging this gap in knowledge
71 requires better understanding of the mechanisms of non-coding mutations underlying
72 heritable disease, along with improved tools to predict and characterise these changes.

73

74 We previously reported a novel inherited cardiac arrhythmia syndrome with widespread ST-
75 segment depression on the electrocardiogram (ECG), termed here ST Depression
76 Syndrome (STDS)⁸. This syndrome is inherited in an autosomal dominant manner and
77 predisposes affected individuals to life-threatening arrhythmias; however, the primary
78 disease-causing mutation remained unknown⁹. Genome-wide association studies (GWAS)
79 for variation in ECG segments, including the PR¹⁰, QRS¹¹, QT^{12,13} and ST¹⁴ intervals, have
80 all highlighted the role of non-coding variants in the electrophysiology of the heart. Here we
81 report a rare non-coding mutation, shared as a founder allele by affected STDS families, as
82 the underlying genetic cause of this novel cardiac arrhythmia syndrome. By applying a
83 machine-learning, genome-engineering and multi-omics approach developed for the
84 deciphering of GWAS variants^{15,16}, we show that the causal mutation, a complex insertion-
85 deletion, repurposes the sequence of a skeletal muscle enhancer to generate a *de novo*
86 gain-of-function cardiomyocyte enhancer that drives increased expression in the heart of the
87 nearby potassium voltage-gated channel encoding gene, *KCNB1*. To our knowledge, this is
88 the first report of a *de novo* enhancer causing Mendelian disease.

89 **Results**

90

91 **Clinical findings in families with ST-depression on the ECG**

92 A total of 14 individuals from five UK families (Fig. 1b) were identified as having autosomal
93 dominant ST Depression Syndrome (STDS) (Fig. 1a). Family 1 was described in the original
94 report of this syndrome (Family B in reference 8), with widespread ST-segment depression
95 on the ECG, starting in childhood then stable through life, with incidences of ventricular
96 arrhythmia resulting in cardiac arrest, and atrial fibrillation (AF) and ventricular contractile
97 impairment developing in later life. The proband of Family 2, IV-4, presented with ventricular
98 arrhythmia in mid-adult life and was noted to have widespread ST-segment depression; an
99 implantable cardioverter-defibrillator (ICD) was implanted when she was in her early thirties.
100 In her 50s and 60s she received multiple ICD shocks for symptomatic polymorphic
101 ventricular tachycardia. She died in her early 60s with severe left ventricular (LV) systolic
102 impairment with an ejection fraction of 10%. Two distant relatives, both in their 30s, were
103 found to have the same ECG phenotype: the ECG features were found in IV:1 when he was
104 investigated for chest pain but found to have normal coronary arteries and then in IV:2, who
105 has no symptoms, on family screening. Neither have had significant arrhythmias. Their
106 father (III:1) died in his mid 60s, with 'abnormal ECG' noted in clinical records but no other
107 information available. The proband of Family 3, also in his 30s, had the abnormal ECG
108 features detected during an insurance medical, had a structurally normal heart and no
109 arrhythmias. His mother had died suddenly in her early 70s with a history of AF, dilated
110 cardiomyopathy and ST-segment depression reported on her ECG. The proband in Family 4
111 presented with syncope as a young adult and was found to have the typical ECG changes of
112 widespread, persistent ST-segment depression. Cardiac MRI was normal and no arrhythmia
113 has been documented on an implanted loop recorder. Her mother died suddenly in her early
114 50s with a clinical record of "sudden cardiac death" but no post-mortem analysis. The
115 proband in Family 5 presented with paroxysmal AF in her 50s. Her sinus rhythm ECGs
116 showed fixed changes typical of familial STDS. Her CT coronary angiogram demonstrated
117 no coronary artery disease, and subsequent cardiac MRI was normal. Her daughter has an
118 identical ECG and is asymptomatic with normal cardiac MRI.

119

120 **Distantly related families with a shared disease locus in a small segment on** 121 **chromosome 20**

122 To identify regions of interest, independent linkage analyses were performed for each of the
123 two larger families, using data generated from single nucleotide polymorphism (SNP) arrays

124 (Family 1: II:1, II:3, II:5, III:1, III:3, III:4, III:5, III:6, IV:1 and IV:2, Family 2: III:5, IV:4, IV:5 and
125 V:1) and WGS (Family 2: IV:1). For Family 1, two regions of the genome on chromosomes
126 12 and 20 showed complete linkage (LOD = 2.41) with ST-segment depression (Fig. 2a,
127 Supplementary Table 1); all other chromosomal regions were excluded with LOD < -2.0.
128 Family 2 did not share the linkage region on chromosome 12, but an overlapping region
129 showing perfect segregation (hg38, chr20:48,212,554-50,048,337, LOD = 1.52) was
130 detected on chromosome 20 (Fig. 2a, Supplementary Table 1), indicating that these two
131 families likely share a single causative locus.

132

133 To explore the possibility that these two STDS families could be distantly related we next
134 examined informative SNPs from the array genotyping to define the haplotypes segregating
135 with disease in the regions of complete linkage in each of Family 1 and 2. In Family 1, this
136 revealed a 6.29 Mbp (10.74cM) segment carried by each of the 7 affected members and not
137 carried by the unaffected family members (Fig. 2b, Supplementary Fig. 1a,b). In Family 2,
138 haplotype analysis revealed a 1.01 Mbp (1.02 cM) region similarly showing complete linkage
139 with STDS, delimited by recombination events within the family (Fig. 2b, Supplementary Fig.
140 1c,d). The haplotypes in this shared region of complete linkage were identical in Family 1
141 and Family 2.—Inspection of this haplotype shows that it is rare, carried by 0.006% of
142 European ancestry individuals in UKBiobank (Supplementary Fig. 2). Thus, this finding
143 provides robust evidence that this sharing has not arisen by chance, but rather Family 1 and
144 2 are distantly related, i.e. share a common ancestor, such that this shared region is
145 identical-by-descent (IBD). Confirmation of a shared IBD region allows linkage data from the
146 two families to be combined for estimation of minimal LOD score; this gives a combined
147 LOD of 4.26 (Fig. 2a).

148

149 In Family 3, whole genome sequence data was available on the proband, but not SNP array
150 data. Genotypes were therefore extracted for informative SNPs in the linkage region on
151 chromosome 20. This revealed an ~ 4.3 Mbp segment in which the disease-associated
152 allele in the risk haplotype in Family 1 was always present in the Family 3 proband's
153 genotype. To estimate the probability that this might have arisen by chance, we examined
154 SNPs not in LD with one another across this region and calculated the combined likelihood
155 of carriage of at least one copy of the relevant allele. This showed that the probability that
156 this might have arisen by chance in less than 2.3×10^{-05} , again indicating that this segment
157 has been passed down IBD from a common ancestor. Taken together these analyses
158 indicate that the disease locus in these families lies on chromosome 20 within the small
159 ~1Mbp region defined by the extent of the IBD segment and haplotype shared by all three.

160

161 **Affected family members share a single non-coding variant**

162 Variant calling and quality-based filtering with Platypus¹⁷, using whole genome sequence
163 data for the six affected individuals from families 1, 2 and 3, resulted in an aggregated
164 dataset containing 6,926,029 variants (6,133,943 SNPs and 792,086 indels). Of these
165 variants, there were 22 novel heterozygous variants shared by the 6 selected affected
166 individuals that were absent from both the general population (gnomAD and 1000G) and the
167 control cohort (Supplementary Table 2). None of these variants affected coding sequence
168 and only one was in the region defined by genetic linkage and the extended area of IBD and
169 haplotype sharing. This variant was a single, small, complex deletion and insertion located in
170 the ~1Mbp shared region on chromosome 20 and carried on the shared affected haplotype
171 (see Supplementary Table 3): NC_000020.11: g.49356862-49356878delinsTCCC, i.e.
172 comprising loss of 17 residues and gain of four others, referred to hereafter as delinsTCCC
173 (Fig. 3). The delinsTCCC variant was absent in all databases searched, including gnomAD
174 and the 100KGP project.

175

176 Sanger sequencing was used to confirm that this variant was absent in unaffected relatives
177 (n=4, Family 1: III:6, Family 2: III:5, IV:5 and V:1) and present in all affected cases from
178 families 1, 2 and 3 (n=12, Family 1: II:1, II:3, III:3, III:4, III:5, IV:1 and IV:2, Family 2: IV:1,
179 IV:2 and IV:4, Family 3: II:1). Finally, Sanger sequencing revealed that the same
180 delinsTCCC was present in both probands from the two additional families subsequently
181 ascertained, Families 4 & 5.

182

183 **In silico analysis of the delinsTCCC variant**

184 The delinsTCCC variant lies in a highly conserved intergenic region of the genome, 6,999 bp
185 downstream of the nearest annotated gene, the potassium channel encoding gene *KCNB1*
186 (Fig. 3) and 78.8 kbp upstream of the nearest transcription start site (*ZNFX1*). Given the
187 non-coding location of this variant we reasoned this region could play a role in transcriptional
188 regulation of genes influencing the ST-segment. Consistent with this hypothesis, it is
189 positioned within 50 kbp of two independent sentinel SNPs identified by a GWAS for ST-
190 segment amplitude¹⁴ (Fig. 4 and Supplementary Dataset 1). Application of a platform
191 designed to decode GWAS signals^{15,16} by considering regulatory, splicing and coding
192 mechanisms, attributed these signals to two moderately linked candidate causal variants
193 (rs6012624, rs6019764, r^2 : 0.715 [EUR]), which both lie in open chromatin in
194 cardiomyocytes. Using a deep convolutional neural network (CNN)^{15,18} trained to predict cell
195 type-specific chromatin activity from sequence we predicted that both GWAS variants alter

196 chromatin accessibility in cardiomyocytes (Supplementary Dataset 1). Published low-
197 resolution (20 kbp) chromosome conformation capture (3C) Hi-C data from cardiomyocytes
198 differentiated from induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC)¹⁹
199 shows that one of the predicted causal GWAS variants and the delinsTCCC variant lie in a
200 region of chromatin that interacts with the *KCNB1* promoter, but not the *ZNF1* promoter
201 (Fig. 4a). These results suggest that altered gene regulation at this locus can affect the ST-
202 segment and may be responsible for STDS.

203

204 Given the sequence conservation surrounding the delinsTCCC variant and the nearby
205 predicted regulatory GWAS SNPs, we investigated Assay for Transposase-Accessible
206 Chromatin-sequencing (ATAC-seq) data from ESC derived cardiomyocyte progenitors¹⁹ and
207 iPSC derived cardiomyocytes from unaffected individuals²⁰, and single cell ATAC-seq
208 (scATAC-seq) from developing embryonic heart²¹ for the presence of open chromatin, which
209 is associated with enhancers. This analysis revealed that the delinsTCCC site does not lie in
210 a region of open chromatin in cardiac cells (Fig. 4a and Fig. 5a) with the nearest open
211 chromatin located ~12 kbp upstream; given the Hi-C chromatin structure we named this site
212 E-139 as it is a putative enhancer and 139 kbp from the *KCNB1* promoter (Fig. 5a,
213 Supplementary Fig. 3). A broader survey of 95 ENCODE DNase1-seq open chromatin
214 datasets^{22,23} and 126 developmental scATAC-seq datasets²¹ shows this region is accessible
215 in skeletal muscle cells and multiple carcinomas (Supplementary Fig. 4) and is designated
216 as a distal enhancer like sequence by ENCODE. Recent work has shown how sequence
217 changes in enhancers can lead to loss of tissue-specificity by optimizing transcription factor
218 binding affinity; including for cardiac enhancers that regulate ECG traits^{24,25}. Given the
219 chromatin accessibility in non-cardiac muscle cells and the nearby ST-segment GWAS
220 signal we hypothesized delinsTCCC may lead to a change in enhancer tissue-specificity, to
221 generate a cryptic *de novo* cardiomyocyte enhancer. Supportive of this hypothesis, the
222 predictions from the deep CNN found that delinsTCCC had the potential to increase
223 chromatin accessibility in cardiomyocytes and smooth muscle cells but not in carcinomas
224 (Fig. 5b, Supplementary Fig. 5). *In silico* mutagenesis of each base pair across the
225 delinsTCCC region showed that a TCCC motif (Fig. 5c), corresponding to several
226 transcription factor families, was important for the predicted gain in accessibility. Consistent
227 with binding-affinity optimization, both ETS and NFKB showed stronger motif matches to the
228 variant sequence than to reference sequence; whereas the E2F motif is only found in the
229 variant sequence (Fig. 5d). These findings strengthen the evidence for this disease-causing
230 variant while supporting the hypothesis for a *de novo* cardiomyocyte enhancer.

231

232 **delinsTCCC generates a cardiac enhancer**

233 To test if delinsTCCC generates an open chromatin site in human cardiomyocytes, we
234 generated iPSC lines (Supplementary Fig. 6) heterozygous for the delinsTCCC variant using
235 CRISPR-Cas9 genome editing (Supplementary Fig. 7). ATAC-seq in cardiomyocytes
236 differentiated from these iPSC showed the presence of a *de novo* open chromatin element
237 which contained the delinsTCCC variant (Fig. 5a). Allelic analysis of reads in this region
238 indicated that over 84% of the reads came from the mutated allele, implying that the peak
239 was specific to the delinsTCCC sequence (Supplementary Fig. 7). Relative levels of histone
240 H3 lysine-4 mono- and tri-methylation (H3K4me1, H3K4me3) can be used to distinguish
241 enhancers and promoters²⁶. We performed Cleavage Under Targets and Release Using
242 Nuclease (CUT&RUN)²⁷ for both H3K4me1, which is primarily at enhancers, and H3K4me3,
243 which is primarily at promoters, in the heterozygous mutant cardiomyocyte cells. Higher
244 levels of H3K4me1 relative to H3K4me3 were detected at the *de novo* element and E-139
245 (Fig. 5a, Supplementary Fig. 8), consistent with ENCODE ChIP-seq for these marks in
246 smooth muscle cells (Supplementary Fig. 4), indicating that they are both likely to be
247 enhancers.

248

249 To determine if the delinsTCCC sequence and the E-139 element function as enhancers we
250 placed each, as well as the equivalent wild-type sequence for the delinsTCCC site (WT),
251 separately upstream of the silent E1b minimal promoter and a GFP reporter gene and
252 generated Tol2-induced transgenic zebrafish embryos. Both the *tg(E-139:GFP)* and the
253 *tg(delinsTCCC:GFP)* transgenic fish showed strong GFP expression in the heart, spread
254 throughout the ventricles in a fairly consistent manner (Fig. 6a,b, Supplementary Table 4).
255 By comparison, the *tg(WT:GFP)* transgenic fish displayed low or negligible GFP expression
256 in this region. Expression in certain other parts of the fish (e.g. the eye) was in keeping with
257 commonly observed autofluorescence (Supplementary Fig. 9).

258

259 In addition to the heart, the *tg(E-139:GFP)* fish also displayed strong expression in other
260 parts of the fish including the head (Fig. 6c, Supplementary Fig. 10). Consistently, E-139
261 was accessible in numerous cerebrum cell-types in ATAC-seq from developing human
262 brains²¹ (Supplementary Fig. 3). This is interesting as the closest gene, *KCNB1*, is known to
263 play a significant role in the brain²⁸. Therefore, while the E-139 element appears to be
264 involved in more ubiquitous expression, the delinsTCCC variant seems to specifically drive
265 gene expression in the heart.

266

267 **delinsTCCC drives higher *KCNB1* expression in cardiomyocytes**

268 To identify the target gene(s) of the *de novo* delinsTCCC enhancer, we generated high-
269 resolution 3C interaction profiles for the three closest active genes (*KCNB1*, *ZNFX1*, *PTGIS*)
270 with nuclear-titrated Capture-C²⁹ using wild-type and heterozygous delinsTCCC iPSC
271 derived cardiomyocytes. Capture-C from the *KCNB1* promoter in the wild-type cells showed
272 strong interaction with E-139 and a proximal CTCF site (C-150) situated 150 kbp upstream
273 of the promoter (Fig. 7). Neither *ZNFX1* nor *PTGIS* showed strong interaction with this
274 region (Supplementary Fig. 11). Capture-C from *KCNB1* in heterozygous delinsTCCC cells,
275 showed significantly higher levels of interaction with fragments covering E-139 compared to
276 the wild-type cells (Fig. 7; two-sided Wilcoxon matched-pairs signed rank test, $p < 0.0001$). To
277 exclude the possibility that these elements interact with more distal genes, we next
278 performed Capture-C experiments from both the delinsTCCC enhancer and E-139. The
279 delinsTCCC site did not show a strong interaction with the *KCNB1* promoter, nor any other
280 promoter, in either wild-type or heterozygous cells. The E-139 enhancer interacted
281 specifically with the *KCNB1* promoter and the level of interaction was significantly increased
282 in the presence of the delinsTCCC allele (two-sided Wilcoxon matched-pairs signed rank
283 test, $p = 0.0094$).

284

285 Finally, to determine whether the increased E-139/*KCNB1* interaction in the presence of the
286 delinsTCCC variant led to higher gene expression, we performed quantitative real-time PCR
287 experiments using iPSC derived cardiomyocytes. Three independent heterozygous clones
288 (C6, C68 and C93), each with multiple differentiations, collectively showed markedly
289 increased *KCNB1* expression (two-sided Mann-Whitney test, $p = 0.0015$) (Fig. 8a).

290

291 To investigate differences in allelic expression, we identified a SNP (rs2229006) within the
292 coding sequence of *KCNB1* (exon 2, NM_004975.4) that was heterozygous in the parental
293 iPSC cell line. By combining public phase data and Nanopore sequencing we determined
294 that the variant allele, rs2229006-C, was in *cis* with the edited delinsTCCC allele in clone C6
295 (Supplementary Fig. 12). RNA sequencing showed a bias for *KCNB1* transcripts arising from
296 the chromosome containing the delinsTCCC variant, with the rs2229006-C allele being 3.8-
297 fold more abundant than the reference rs2229006-G allele (Supplementary Table 5). These
298 findings corroborate a mechanism whereby a *de novo* enhancer, created by the delinsTCCC
299 variant, leads to cardiac specific *KCNB1* upregulation through an increased interaction
300 between E-139 and the *KCNB1* promoter (Fig. 8b).

301 Discussion

302

303 We have utilised a multi-omics, genome engineering and machine learning^{15,16} approach to
304 identify and characterise a novel gain-of-function non-coding disease-causing variant
305 responsible for a recently described cardiac arrhythmia syndrome, STSD^{8,30}. This syndrome
306 is associated with widespread ST-segment depression on the ECG and predisposes
307 affected individuals to cardiac events including sudden cardiac death and heart failure. The
308 responsible variant, delinsTCCC, generates a cryptic cardiomyocyte enhancer which drives
309 higher expression of the potassium channel encoding gene, *KCNB1*.

310

311 Cardiac arrhythmia syndromes are most commonly associated with variants in ion channel
312 genes³¹. Consistent with this, the causal variant identified in this study enhances the
313 expression in the heart of the *KCNB1*-encoded, pore-forming subunit of the voltage-gated
314 potassium channel Kv2.1. This channel acts as a delayed rectifier, propagating current in a
315 wide range of electrically active cell types across many organ systems. Kv2.1 plays an
316 important role in the repolarisation phase of the action potential in rodent hearts^{32,33}, is
317 expressed in human atrial³⁴⁻³⁶ and ventricular cells^{35,36}, and binds ion channel beta-subunits
318 from the KCNE family³⁷ known to contribute to other cardiac arrhythmia syndromes such as
319 the Long-QT syndrome^{38,39}. However, rather than causing cardiac disease, pathogenic
320 *KCNB1* coding variants have been shown to cause neurological disorders, specifically forms
321 of developmental and epileptic encephalopathy⁴⁰. Much attention has been devoted to the
322 study of Kv2.1 in the human brain, largely due to its high expression in this region⁴¹.
323 Interestingly, our study identified the regulatory element proximal to the delinsTCCC
324 enhancer, E-139, as an interactor of the *KCNB1* gene promoter and we confirm its ability of
325 driving reporter gene expression in zebrafish brain. The broad clinical spectrum of subjects
326 with different *KCNB1* variants emphasises the cell-type specific impact of regulatory
327 changes which determine which organs are affected, and hence the phenotypes of these
328 inherited conditions.

329

330 The hallmark phenotype of resting ST-segment depression on the surface ECG in STDS
331 implies transmural heterogeneity of currents underlying the cardiac action potential, thereby
332 creating a transmural gradient (analogous to the ST-segment shifts seen acutely in the
333 context of subendocardial ischaemia or myocardial infarction)^{42,43}. Therefore, we
334 hypothesise that the delinsTCCC enhancer results in differential increases in *KCNB1*
335 expression, and hence Kv2.1 activity, in different layers of the myocardium – a property
336 commonly associated with cardiac ion channels⁴⁴. A shorter endocardial action potential,

337 induced by an endocardial increase in expression of the Kv2.1 channel, would promote
338 current flow from epicardial sites with longer action potentials to generate ST depression on
339 the surface ECG. This is the inverse of the gradient seen in Brugada Syndrome which
340 promotes localised ST elevation associated with different transmural action potential
341 durations where the epicardial action potential duration is relatively short^{45,46}. These
342 gradients require electrotonic uncoupling to be maintained. Indeed, the fact that the ST
343 depression develops 80ms after the J point would be compatible with such differences
344 developing in phase 3 and 4 of the action potential when Kv2.1 is active. Such gradients set
345 up potential sites for phase 2 re-entry following an ectopic beat initiating the polymorphic
346 ventricular arrhythmias described in this rare familial condition⁴⁷.

347

348 The delinsTCCC variant underlying STDS adds to the growing knowledge of non-coding
349 regulatory variants associated with ECG traits. Previous reports, including a number of
350 GWAS¹⁰⁻¹⁴, have identified non-coding regions important for the ST¹⁴, QT^{12,13,48-50}, PR^{10,51-53}
351 and QRS^{11,51-53} intervals. However, identifying specific target genes and their associated
352 functional effects is still a huge challenge. This has limited the detection and inclusion of
353 pathogenic non-coding variants in clinical practice. Furthermore, while pairing genes to their
354 regulatory elements can be carried out using a combination of chromosome conformation
355 capture techniques⁵⁴ and open chromatin atlases²¹, these methods are of little use for the
356 identification of *de novo* enhancer variants. Therefore, our study highlights the value of
357 combining these rich resources with ongoing 'classic' family studies, cellular models and
358 machine learning to improve non-coding variant detection and validation.

359

360 Gain-of-function mechanisms are an important consideration when trying to decipher non-
361 coding effects. Despite reports of gain-of-function variants within existing enhancers in
362 common disease, rare disease and malignancy⁵⁵⁻⁵⁷, we believe this is the first description of
363 an entirely *de novo* cryptic enhancer causing a Mendelian disorder. Variants creating *de*
364 *novo* regulatory elements may conceivably be more common than expected. Recently, a
365 single nucleotide variant which causes α -thalassemia was fully characterised as generating
366 a gain-of-function cryptic promoter which blocks interaction between the two α -globin
367 encoding genes and their cognate enhancers⁵⁸. Additionally, in T-cell acute lymphoblastic
368 leukaemia, gain-of-function deletions upstream of the *TAL1* oncogene generate a *de novo*
369 enhancer which drives higher gene expression⁵⁹. Similarly, in several autosomal dominant
370 heritable diseases, including brachydactyly-anonychia⁶⁰, Keratolytic Winter Erythema⁶¹,
371 Haas-type polysyndactyly and Laurin-Sandrow syndrome⁶², as well as syndactyly and

372 craniosynostosis⁶³, duplications of developmental gene enhancers cause disease through
373 gain-of-function.

374

375 Intriguingly, our 3C approach did not detect significant changes in the interaction between
376 the *de novo* cryptic enhancer and the *KCNB1* promoter. This suggests that the delinsTCCC
377 enhancer may function in an indirect manner, by promoting stronger interaction between E-
378 139 and the *KCNB1* promoter. Recent work to dissect the role of the five independent
379 elements of the mouse alpha-globin super enhancer has shown that while some elements
380 look like classical tissue-specific enhancers in reporter assays, they instead act as
381 facilitators for nearby enhancers in their native context⁶⁴. This is consistent with the tissue-
382 specific GFP expression driven by the delinsTCCC enhancer in the Zebrafish reporter
383 assay. This mechanism is compatible with two current models for gene regulation. In the first
384 model, the loop extrusion model⁶⁵, the delinsTCCC enhancer could be recruiting additional
385 cohesin⁶⁶, promoting an increase in the frequency of the interaction between *KCNB1* and E-
386 139. In contrast to this model, the second involves an increase in bound transcription factors
387 leading to more frequent or stable phase-separation⁶⁷. Further research is required to better
388 understand these models and their contribution to disease.

389

390 In addition to specific cardiovascular conditions, including cardiac arrhythmias⁸, ischemia or
391 coronary heart disease⁶⁸, ST-segment depression on the ECG is associated with an
392 increased risk of unexplained sudden cardiac death in the general population⁶⁹. GWAS have
393 identified numerous common variants that are associated with ST-segment variability¹⁴,
394 some of which are near the delinsTCCC variant. Therefore, additional studies of non-coding
395 variants associated with ECG alterations from both GWAS and Mendelian disease will likely
396 improve our general understanding of both gene regulation and cardiovascular disease.

397

398

399 **Acknowledgements**

400 The authors are grateful to Nadav Ahituv from the University of California, San Francisco for
401 gifting the E1b-GFP-Tol2 vector. We would also like to thank Charlotte Ives, Inherited
402 Arrhythmia Clinical Nurse Specialist, Barts Health NHS Trust, London, and Ellie Quinn from
403 Royal Brompton and Harefield Hospitals for assistance with patient records. Additionally, we
404 would like to thank the Oxford Genomics Centre at the Centre for Human Genetics for the
405 generation and initial processing of sequencing data.

406

407 This work was supported by funding from the British Heart Foundation (BHF), Wellcome
408 Trust (nos.090532/Z/09/Z and 203141/Z/16/Z to H.W.) and the National Institute for Health
409 Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of
410 the authors and not necessarily those of the NHS, the NIHR or the Department of Health or
411 Wellcome Trust. J.R.H received funding from a Wellcome Strategic Award (no.
412 106130/Z/14/Z), Wellcome Discovery Award (225220/Z/22/Z) and Medical Research Council
413 Core Funding (no. MC_UU_00016/14 and MC_UU_00029/3). R.S. was supported by a
414 Wellcome Doctoral Programme (no. 203728/Z/16/Z). R.A.B was funded by a Sir Henry
415 Wellcome Fellowship (no. 209181/Z/17/Z). S.D. and S.N. were supported by a BHF
416 Fellowship (no. FS/1735/32929), MRC project grant (no. MR/S01019X/1) and by Leducq
417 Foundation grant 18CVD03. P.L. was supported by UCL/UCLH and Barts NIHR Biomedical
418 Research Centres. H.W.'s laboratory is supported by the British Heart Foundation's Big Beat
419 Challenge award to CureHeart (BBC/F/21/220106).

420

421

422 **Author contributions**

423 C.P.D.V, D.J.D., A.J.S., S.N., P.R., M.E.G., R.A.B., M.L., C.W., A.T. performed experiments.
424 C.P.D.V, D.J.D., A.T.P., A.J.S., S.N., E.G., A.G., M.F., R.S., D.P., S.L, S.S, H.R. processed
425 data and performed analyses.

426 C.P.D.V, D.J.D. designed experiments.

427 C.P.D.V., D.J.D., A.T.P., A.J.S., S.N, E.G., A.G., M.F., P.R, D.P. wrote the manuscript and
428 made figures.

429 E.O., R.H., E.R., G.S, P.L., H.W. collected and evaluated clinical data.

430 C.P.D.V, A.J.S. cultured iPSC derived cardiomyocytes.

431 S.N. performed zebrafish investigations.

432 P.R. produced CRISPR-Cas9 edited iPSC cell lines.
433 M.L, C.W., A.T. performed nanopore sequencing.
434 M.F., B.D., D.B., J.C.T., C.R., S.D.V., J.R.H., H.W. provided supervision.
435 H.W., J.R.H., acquired funding, oversaw the work, and revised the manuscript.
436 H.W. conceived the work.

437


438 **Disclosures**

439 J.R.H. is a founder, shareholder and director of Nucleome Therapeutics.
440 J.R.H. holds patents for Capture-C (nos. WO2017068379A1, EP3365464B1
441 and US10934578B2).
442 R.H. is currently employed at Novartis and has stock ownership for AstraZeneca and
443 Illumina
444 D.J.D. is currently employed by Blue Matter Consulting
445 R.S is currently employed by Glaxo-Smith Klein
446 The other authors declare no competing interests.

447 **Figures**

448

449




451


452

453 **Fig. 1. Families with ST-depression syndrome (STDS).** **a**, Example ECG lead II traces
454 showing normal versus ST-segment depression in affected members from five independent
455 UK families. **b**, Partial pedigrees of families identified with STDS. Affected individuals are
456 shaded in black. The full pedigrees have not been disclosed to comply with medRxiv's
457 policies. Full disclosure of the pedigrees is available upon request from the authors.

458



459



460

461

462

463

464

465

466

467

468


469

470

471

472


Fig. 2. A shared, identical-by-descent, disease locus on chromosome 20. a, Linkage analysis identified a single linkage region shared by family 1 (blue) and family 2 (green) on chromosome 20. The blue bar denotes the 6.29Mbp region in complete linkage in Family 1 and is displayed in b). **b)** 3-4 markers were selected per cM and the linkage boundaries were determined based on recombination events. The risk haplotypes of families 1 & 2 are shown and are seen to be identical in a ~1Mbp region; as the haplotype is rare this indicates identity-by-descent, allowing combining of the LOD scores (black). Genotypes of the affected family 3 member are shown above; SNPs in linkage with each other are highlighted in grey and excluded from probability estimation for Family 3.



473
474
475
476
477

Fig. 3. The delinsTCCC variant and flanking sequence. Sequence and relative chromosome 20 position (hg38) of the indel variant. Green conservation peaks represent PhastCons conservation predictions using 100 vertebrates.

478



479


480

481 **Fig. 4. *In silico* analysis of the novel delinsTCCC variant and flanking sequence. a,** HiC

482 interaction plots for ESC and iPSC derived cardiomyocytes, ATAC-seq peaks for iPSC

483 derived cardiomyocytes, genes and delinsTCCC location. **b,** SNPs in linkage ($r^2 \geq 0.8$ [EUR])


484 with ST-segment GWAS sentinel SNPs rs11907908 (blue) and rs2202261 (red).



485
486
487
488
489
490
491
492
493
494
495
496
497

Fig. 5. Accessibility analysis of the delinsTCCC variant sequence. **a**, ATAC sequencing analysis of published data (GSE89895, GSE106690) for cardiomyocytes (CM) and progenitors, including mesoderm (MES) and cardiac progenitors (CP), derived from differentiation of embryonic stem cells (ESC), or induced pluripotent stem cells (iPSC). Cardiomyocytes either lacked (WT) or were heterozygous (delinsTCCC/WT) for the delinsTCCC variant. CTCF ChIP-seq (Erythroid, GSE125926) shows tissue-invariant boundary elements. H3K4me1 and H4K4me3 CUT&RUN in delinsTCCC heterozygous cardiomyocytes show enhancers and promoters respectively. Inset region is chr20:49,327,000-49,367,000 (hg38) with 5-pixel window. **b**, deep CNN accessibility predictions. Error bars denote one standard deviation of accessibility score for the 13 possible 1 kbp sequences covering the indel site. **c**, *in silico* mutagenesis for the


498 delinsTCCC site indicating a possible motif including the TCCC insert. **d**, left panel shows
499 the colour coded FIMO derived predicted motifs from both the reference and variant
500 delinsTCCC sequence. The right panel shows the PhyloP sequence conservation plotted
501 over the reference sequence (Ref) with the deleted sequence high-lighted in red and with
502 the position of motif matches and FIMO p-values below. The delinsTCCC variant sequence
503 is shown below with the 4 base-pair insertion highted in blue and with the position of motif
504 matches and FIMO p-values below, showing the creation of a strong E2F7 motif and the
505 rearrangement and increase in scores for pre-existing motifs.



506


507 **Fig. 6. Enhancer variant expression in zebrafish embryos.** **a**, GFP expression for
508 transgenic fish containing the E-139, wild type (WT) or delinsTCCC variant sequence. The
509 asterisk indicates the location of the heart. The Myl7 cardiac marker is overlaid in red. DIC =
510 differential interference contrast. **b**, Total GFP levels observed in the hearts of transgenic
511 zebrafish; n represents the total number of transgenic zebrafish embryos per category. **c**, E-
512 139 transgenic fish displayed strong expression in the brain indicated by the arrows.

513
514



515
516
517
518
519
520
521
522
523

Fig. 7. Chromatin conformation and interaction assays. ATAC sequencing analysis of experimental data from iPSC derived cardiomyocytes (CM) heterozygous (delinsTCCC/WT) for the delinsTCCC variant. CTCF ChIP-seq shows boundary elements. Capture-C from the *KCNB1* promoter, delinsTCCC enhancer, and the E-139 enhancer. Solid lines show mean (n=3 independent samples) with one standard deviation (shading). Subtraction tracks show per *DpnII* fragment difference. Enhancer and promoter regions indicated below display regions of significant difference.



524

525

Fig. 8. *KCNB1* upregulation by the delinsTCCC variant. **a**, Fold change in *KCNB1* expression versus the housekeeping gene (*GAPDH*) detected by qPCR for reference (WT n=4 independent samples/differentiations) and heterozygous delinsTCCC clones (C6 n=3, C68 n=4, C93 n=4 independent samples/differentiations). The mean for each group is represented by the black horizontal line, bars show standard error of the mean and the p-value from two-sided Mann-Whitney test is indicated. **b**, Model illustrating a proposed regulatory mechanism with the delinsTCCC variant indirectly enhancing *KCNB1* transcription.

532

533 **References**

- 534 1. Taylor, J. C. *et al.* Factors influencing success of clinical genome sequencing across a
535 broad spectrum of disorders. *Nat. Genet.* **47**, 717–726 (2015).
- 536 2. Trujillano, D. *et al.* Clinical exome sequencing: results from 2819 samples reflecting 1000
537 families. *Eur. J. Hum. Genet.* **25**, 176–182 (2017).
- 538 3. Wright, C. F., FitzPatrick, D. R. & Firth, H. V. Paediatric genomics: diagnosing rare disease
539 in children. *Nat. Rev. Genet.* **19**, 253–268 (2018).
- 540 4. Lee, H. *et al.* Diagnostic utility of transcriptome sequencing for rare Mendelian diseases.
541 *Genet. Med.* **22**, 490–499 (2020).
- 542 5. Gloss, B. S. & Dinger, M. E. Realizing the significance of noncoding functionality in
543 clinical genomics. *Exp. Mol. Med.* **50**, 97 (2018).
- 544 6. Maurano, M. T. *et al.* Systematic localization of common disease-associated variation in
545 regulatory DNA. *Science* **337**, 1190–1195 (2012).
- 546 7. French, J. D. & Edwards, S. L. The Role of Noncoding Variants in Heritable Disease.
547 *Trends Genet.* **36**, 880–891 (2020).
- 548 8. Bundgaard, H. *et al.* A novel familial cardiac arrhythmia syndrome with widespread ST-
549 segment depression. *N. Engl. J. Med.* **379**, 1780–1781 (2018).
- 550 9. Christensen, A. H. & Bundgaard, H. The Novel Familial ST-Depression Syndrome -
551 Current Knowledge and Perspectives. *Card. Electrophysiol. Clin.* **15**, 343–348 (2023).
- 552 10. Ntalla, I. *et al.* Multi-ancestry GWAS of the electrocardiographic PR interval identifies
553 202 loci underlying cardiac conduction. *Nat. Commun.* **11**, 1–12 (2020).
- 554 11. Sotoodehnia, N. *et al.* Common variants in 22 loci are associated with QRS duration and
555 cardiac ventricular conduction. *Nat. Genet.* **42**, 1068–1076 (2010).

- 556 12. Newton-Cheh, C. *et al.* Common variants at ten loci influence QT interval duration in the
557 QTGEN Study. *Nat. Genet.* **41**, 399–406 (2009).
- 558 13. Pfeufer, A. *et al.* Common variants at ten loci modulate the QT interval duration in the
559 QTSCD Study. *Nat. Genet.* **41**, 407–414 (2009).
- 560 14. Verweij, N. *et al.* Twenty-eight genetic loci associated with ST-T-wave amplitudes of the
561 electrocardiogram. *Hum. Mol. Genet.* **25**, 2093–2103 (2016).
- 562 15. Downes, D. J. *et al.* An integrated platform to systematically identify causal variants and
563 genes for polygenic human traits. *Prepr. BioRxiv* <https://doi.org/10.1101/813618> (2019).
- 564 16. Downes, D. J. *et al.* Identification of LZTFL1 as a candidate effector gene at a COVID-19
565 risk locus. *Nat. Genet.* **53**, 1606–1615 (2021).
- 566 17. Rimmer, A. *et al.* Integrating mapping-, assembly-and haplotype-based approaches for
567 calling variants in clinical sequencing applications. *Nat. Genet.* **46**, 912–918 (2014).
- 568 18. Schwessinger, R. *et al.* DeepC: predicting 3D genome folding using megabase-scale
569 transfer learning. *Nat. Methods* 1–7 (2020).
- 570 19. Bertero, A. *et al.* Dynamics of genome reorganization during human cardiogenesis reveal
571 an RBM20-dependent splicing factory. *Nat. Commun.* **10**, 1–19 (2019).
- 572 20. Banovich, N. E. *et al.* Impact of regulatory variation across human iPSCs and
573 differentiated cells. *Genome Res.* **28**, 122–131 (2018).
- 574 21. Domcke, S. *et al.* A human cell atlas of fetal chromatin accessibility. *Science* **370**,
575 eaba7612 (2020).
- 576 22. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human
577 genome. *Nature* **489**, 57–74 (2012).

- 578 23. ENCODE Project Consortium *et al.* Expanded encyclopaedias of DNA elements in the
579 human and mouse genomes. *Nature* **583**, 699–710 (2020).
- 580 24. Farley, E. K. *et al.* Suboptimization of developmental enhancers. *Science* **350**, 325–328
581 (2015).
- 582 25. Jindal, G. A. *et al.* Single-nucleotide variants within heart enhancers increase binding
583 affinity and disrupt heart development. *Dev. Cell* **58**, 2206-2216.e5 (2023).
- 584 26. Kowalczyk, M. S. *et al.* Intragenic Enhancers Act as Alternative Promoters. *Mol. Cell* **45**,
585 447–458 (2012).
- 586 27. Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution
587 mapping of DNA binding sites. *eLife* **6**, e21856 (2017).
- 588 28. Murakoshi, H. & Trimmer, J. S. Identification of the Kv2.1 K⁺ Channel as a Major
589 Component of the Delayed Rectifier K⁺ Current in Rat Hippocampal Neurons. *J.*
590 *Neurosci.* **19**, 1728–1735 (1999).
- 591 29. Downes, D. J. *et al.* High-resolution targeted 3C interrogation of cis -regulatory element
592 organization at genome-wide scale. *Nat. Commun.* **12**, 531 (2021).
- 593 30. Christensen, A. H. *et al.* Electrocardiographic Findings, Arrhythmias, and Left Ventricular
594 Involvement in Familial ST-Depression Syndrome. *Circ. Arrhythm. Electrophysiol.* **15**,
595 e010688 (2022).
- 596 31. Hedley, P. L. *et al.* The genetic basis of long QT and short QT syndromes: A mutation
597 update. *Hum. Mutat.* **30**, 1486–1511 (2009).
- 598 32. Xu, H. *et al.* Attenuation of the slow component of delayed rectification, action potential
599 prolongation, and triggered activity in mice expressing a dominant-negative Kv2 α
600 subunit. *Circ. Res.* **85**, 623–633 (1999).

- 601 33. Zhou, J. *et al.* Regional upregulation of Kv2. 1-encoded current, IK, slow2, in Kv1DN mice
602 is abolished by crossbreeding with Kv2DN mice. *Am. J. Physiol.-Heart Circ. Physiol.* **284**,
603 H491–H500 (2003).
- 604 34. Van Wagoner, D. R., Pond, A. L., McCarthy, P. M., Trimmer, J. S. & Nerbonne, J. M.
605 Outward K⁺ current densities and Kv1. 5 expression are reduced in chronic human atrial
606 fibrillation. *Circ. Res.* **80**, 772–781 (1997).
- 607 35. Gaborit, N. *et al.* Regional and tissue specific transcript signatures of ion channel genes
608 in the non-diseased human heart. *J. Physiol.* **582**, 675–693 (2007).
- 609 36. Ördög, B. *et al.* Gene expression profiling of human cardiac potassium and sodium
610 channels. *Int. J. Cardiol.* **111**, 386–393 (2006).
- 611 37. McCrossan, Z. A., Roepke, T. K., Lewis, A., Panaghie, G. & Abbott, G. W. Regulation of the
612 Kv2. 1 potassium channel by MinK and MiRP1. *J. Membr. Biol.* **228**, 1–14 (2009).
- 613 38. Splawski, I., Tristani-Firouzi, M., Lehmann, M. H., Sanguinetti, M. C. & Keating, M. T.
614 Mutations in the hminK gene cause long QT syndrome and suppress IKs function. *Nat.*
615 *Genet.* **17**, 338–340 (1997).
- 616 39. Abbott, G. W. *et al.* MiRP1 Forms IKr Potassium Channels with HERG and Is Associated
617 with Cardiac Arrhythmia. *Cell* **97**, 175–187 (1999).
- 618 40. Kang, S. K. *et al.* Spectrum of KV2.1 Dysfunction in KCNB1-Associated
619 Neurodevelopmental Disorders. *Ann. Neurol.* **86**, 899–912 (2019).
- 620 41. Trimmer, J. S. Subcellular Localization of K⁺ Channels in Mammalian Brain Neurons:
621 Remarkable Precision in the Midst of Extraordinary Complexity. *Neuron* **85**, 238–256
622 (2015).

- 623 42. Hopenfled, B., Stinstra, J. G. & Macleod, R. S. Mechanism for ST depression associated
624 with contiguous subendocardial ischemia. *J. Cardiovasc. Electrophysiol.* **15**, 1200–1206
625 (2004).
- 626 43. Okada, J.-I. *et al.* Ionic mechanisms of ST segment elevation in electrocardiogram during
627 acute myocardial infarction. *J. Physiol. Sci. JPS* **70**, 36 (2020).
- 628 44. Schram, G., Pourrier, M., Melnyk, P. & Nattel, S. Differential Distribution of Cardiac Ion
629 Channel Expression as a Basis for Regional Specialization in Electrical Function. *Circ. Res.*
630 **90**, 939–950 (2002).
- 631 45. Bhar-Amato, J. *et al.* Pharmacological Modulation of Right Ventricular Endocardial-
632 Epicardial Gradients in Brugada Syndrome. *Circ. Arrhythm. Electrophysiol.* **11**, e006330
633 (2018).
- 634 46. Antzelevitch, C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. *J.*
635 *Cardiovasc. Electrophysiol.* **12**, 268–272 (2001).
- 636 47. Yan, G.-X., Lankipalli, R. S., Burke, J. F., Musco, S. & Kowey, P. R. Ventricular
637 repolarization components on the electrocardiogram: cellular basis and clinical
638 significance. *J. Am. Coll. Cardiol.* **42**, 401–409 (2003).
- 639 48. Kapoor, A. *et al.* An enhancer polymorphism at the cardiomyocyte intercalated disc
640 protein NOS1AP locus is a major regulator of the QT interval. *Am. J. Hum. Genet.* **94**,
641 854–869 (2014).
- 642 49. Kapoor, A. *et al.* Multiple SCN5A variant enhancers modulate its cardiac gene expression
643 and the QT interval. *Proc. Natl. Acad. Sci.* **116**, 10636–10645 (2019).
- 644 50. De Villiers, C. P. *et al.* AKAP9 is a genetic modifier of congenital long-QT syndrome type
645 1. *Circ. Cardiovasc. Genet.* **7**, 599–606 (2014).

- 646 51. Holm, H. *et al.* Several common variants modulate heart rate, PR interval and QRS
647 duration. *Nat. Genet.* **42**, 117 (2010).
- 648 52. Bezzina, C. R. *et al.* Common Sodium Channel Promoter Haplotype in Asian Subjects
649 Underlies Variability in Cardiac Conduction. *Circulation* **113**, 338–344 (2006).
- 650 53. van Weerd, J. H. *et al.* Trait-associated noncoding variant regions affect TBX3 regulation
651 and cardiac conduction. *eLife* **9**, e56697 (2020).
- 652 54. Davies, J. O. J., Oudelaar, A. M., Higgs, D. R. & Hughes, J. R. How best to identify
653 chromosomal interactions: a comparison of approaches. *Nat. Methods* **14**, 125–134
654 (2017).
- 655 55. Gupta, R. M. *et al.* A Genetic Variant Associated with Five Vascular Diseases Is a Distal
656 Regulator of Endothelin-1 Gene Expression. *Cell* **170**, 522-533.e15 (2017).
- 657 56. Mika, K. M., Li, X., DeMayo, F. J. & Lynch, V. J. An Ancient Fecundability-Associated
658 Polymorphism Creates a GATA2 Binding Site in a Distal Enhancer of HLA-F. *Am. J. Hum.*
659 *Genet.* **103**, 509–521 (2018).
- 660 57. Wright, J. B., Brown, S. J. & Cole, M. D. Upregulation of c-MYC in cis through a Large
661 Chromatin Loop Linked to a Cancer Risk-Associated Single-Nucleotide Polymorphism in
662 Colorectal Cancer Cells. *Mol. Cell. Biol.* **30**, 1411–1420 (2010).
- 663 58. Bozhilov, Y. K. *et al.* A gain-of-function single nucleotide variant creates a new promoter
664 which acts as an orientation-dependent enhancer-blocker. *Nat. Commun.* **12**, 3806
665 (2021).
- 666 59. Mansour, M. R. *et al.* An oncogenic super-enhancer formed through somatic mutation
667 of a noncoding intergenic element. *Science* **346**, 1373–1377 (2014).

- 668 60. Kurth, I. *et al.* Duplications of noncoding elements 5' of SOX9 are associated with
669 brachydactyly-anonychia. *Nat. Genet.* **41**, 862–863 (2009).
- 670 61. Ngcungcu, T. *et al.* Duplicated Enhancer Region Increases Expression of CTSB and
671 Segregates with Keratolytic Winter Erythema in South African and Norwegian Families.
672 *Am. J. Hum. Genet.* **100**, 737–750 (2017).
- 673 62. Lohan, S. *et al.* Microduplications encompassing the Sonic hedgehog limb enhancer ZRS
674 are associated with Haas-type polysyndactyly and Laurin-Sandrow syndrome. *Clin.*
675 *Genet.* **86**, 318–325 (2014).
- 676 63. Will, A. J. *et al.* Composition and dosage of a multipartite enhancer cluster control
677 developmental expression of *Ihh* (Indian hedgehog). *Nat. Genet.* **49**, 1539–1545 (2017).
- 678 64. Blayney, J. W. *et al.* Super-enhancers include classical enhancers and facilitators to fully
679 activate gene expression. *Cell* **186**, 5826–5839.e18 (2023).
- 680 65. Fudenberg, G. *et al.* Formation of Chromosomal Domains by Loop Extrusion. *Cell Rep.*
681 **15**, 2038–2049 (2016).
- 682 66. Rinzema, N. J. *et al.* *Building Regulatory Landscapes: Enhancer Recruits Cohesin to*
683 *Create Contact Domains, Engage CTCF Sites and Activate Distant Genes.*
684 2021.10.05.463209 <https://www.biorxiv.org/content/10.1101/2021.10.05.463209v1>
685 (2021) doi:10.1101/2021.10.05.463209.
- 686 67. Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K. & Sharp, P. A. A Phase Separation
687 Model for Transcriptional Control. *Cell* **169**, 13–23 (2017).
- 688 68. Hanna, E. B. & Glancy, D. L. ST-segment depression and T-wave inversion: Classification,
689 differential diagnosis, and caveats. *Cleve. Clin. J. Med.* **78**, 404–414 (2011).

690 69. Deng, X.-Q., Xu, X.-J., Wu, S.-H., Li, H. & Cheng, Y.-J. Association between resting painless
691 ST-segment depression with sudden cardiac death in middle-aged population: A
692 prospective cohort study. *Int. J. Cardiol.* **301**, 1–6 (2020).

693

694

695 **WGS500 Consortium membership: names and affiliations of authors**

696 Steering Committee: Peter Donnelly (Chair)¹, John Bell², David Bentley³, Gil McVean¹,
697 Peter Ratcliffe¹, Jenny C. Taylor^{1,4}, Andrew Wilkie^{4,5}

698 Operations Committee: Peter Donnelly (Chair)¹, John Broxholme¹, David Buck¹, Jean-
699 Baptiste Cazier¹, Richard Cornall¹, Lorna Gregory¹, Julian Knight¹, Gerton Lunter¹, Gil
700 McVean¹, Jenny C. Taylor^{1,4}, Ian Tomlinson^{1,4}, Andrew Wilkie^{4,5}

701 Sequencing & Experimental Follow up: David Buck (Lead)¹, Christopher Allan¹, Moustafa
702 Attar¹, Angie Green¹, Lorna Gregory¹, Sean Humphray³, Zoya Kingsbury³, Sarah Lambie¹,
703 Lorne Lonie¹, Alistair T. Pagnamenta¹, Paolo Piazza¹, Guadalupe Polanco¹, Amy Trebes¹

704 Data Analysis: Gil McVean¹ (Lead), Peter Donnelly¹, Jean-Baptiste Cazier¹, John
705 Broxholme¹, Richard Copley¹, Simon Fiddy¹, Russell Grocock³, Edouard Hatton¹, Chris
706 Holmes¹, Linda Hughes¹, Peter Humburg¹, Alexander Kanapin¹, Stefano Lise¹, Gerton
707 Lunter¹, Hilary C. Martin¹, Lisa Murray³, Davis McCarthy¹, Andy Rimmer¹, Natasha
708 Sahgal¹, Ben Wright¹, Chris Yau⁶

709

710 ¹The Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK

711 ²Office of the Regius Professor of Medicine, Richard Doll Building, Roosevelt Drive,
712 Oxford, OX3 7LF, UK

713 ³Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Essex, CB10 1XL,
714 UK

715 ⁴NIHR Oxford Biomedical Research Centre, Oxford, UK

716 ⁵Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford
717 OX3 9DS, UK

718 ⁶Imperial College London, South Kensington Campus, London, SW7 2AZ, UK